Good MorningEquity markets tread water on Monday as participants brace for a busy week. Both the economic and earnings calendars are filled this week and promise to bring market-moving news. The question is whether the news will move the market firmly in one direction or if volatility will reign supreme. On the earnings front, reports from J.B. Hunt, Netflix, Abbott Laboratories and Proctor & Gamble are at the top of the list and promise to give a deeper view into a broad swath of the economy.
On the economic front, the market is waiting for a host of reports on manufacturing, the housing market and the Index of Leading Indicators. The Index of Leading Indicators is of particular concern because it has been negative for over a year and is expected to accelerate its decline this month. This is a signal of recessionary pressures and one that is getting louder as the months go by. Featured: Free Stock Analysis Report: Get Buy, Sell, or Hold Recommendation (Vector Vest) 
|
Markets | | |
Among large-cap energy names, Pioneer Natural Resources Co. (NYSE: PXD), Devon Energy Corp. (NYSE: DVN) and Kinder Morgan Inc. (NYSE: KMI) pay some of the highest dividend yields among their sector peers in the S&P 500.
While yield is certainly a crucial component of investing (and high ... Read the Full Story |
|
From Our PartnersWarren Buffett says that a "climate of fear is your friend when investing; a euphoric world is your enemy."
"The time to buy is when there's blood in the streets, even if the blood is your own." With a good deal of fear priced into the tech sector, here are five hot stocks to consider.
| | Click Here to Download the FREE Report |
|
Markets | | | Asian shares were trading mixed Wednesday, as investors took a wait-and-see attitude ahead of earnings reports and possible moves by central banks. Japan's benchmark Nikkei 225 slipped 0.2% in morning trading to 28,590.40. Australia's S&P/ASX 200 edged up 0.1% to 7,370.70. South Korea's Kospi ga... Read the Full Story |
|
Markets | | |
State Street (NYSE: STT) shares have declined by more than 10% in today's trading session, past any standard deviations experienced in the past on a normalized basis by investors. This reaction is attributed to market sentiment reflecting what has been reported in the latest quarter... Read the Full Story |
|
From Our PartnersPorter Stansberry here -- I reveal the shocking changes this Obama policy will usher in… what it means for you, your family, and your finances… and how you can prepare for this new American era.
Stream my new documentary at no cost today. | | Click here now - and watch it before it is removed |
|
Markets | | |
A new upgrade from JPMorgan Chase & Co. (NYSE: JPM) suggests Ollies Bargain Outlet Holdings, Inc (NASDAQ: OLLI) has value. They upgraded the stock from Underweight to Neutral, which is not an inspiring move but 1 that helps lift the ceiling for the market. An increase in confidence was cited, ... Read the Full Story |
|
Markets | | | House Speaker Kevin McCarthy pledged Monday to pass legislation to raise the nation's debt ceiling — but only on condition of capping future federal spending increases at 1% — as he lashed out at President Joe Biden for refusing to engage in budget-cutting negotiations to prevent a debt crisis.In a ... Read the Full Story |
|
From Our PartnersJoin thousands of confident Gold-IRA investors and invest in precious metals with confidence! Get your FREE 2023 Gold Guide endorsed by Mike Huckabee and gain expert insights into how you can solidify your savings. Don't wait and let this life changing opportunity pass you by, the Free Gold Guide is your go-to resource for investing in gold. | | Take The First Step in Securing Your Future Security Now! |
|
Markets | | | The fragmentation of the world economy into rival blocs led by the United States and China threatens to destabilize global commerce, increase inflation and weaken growth, Christine Lagarde, the president of the European Central Bank, warned Monday Read the Full Story |
|
Markets | | |
We knew it was coming, and we’ve written about it already, but this morning’s release of their Q1 numbers just confirmed Charles Schwab Corporation’s (NYSE: SCHW) recovery has begun. It was a breath of fresh air for investors of the online broker. Having seen their shares decimat... Read the Full Story |
|
Markets | | |
PepsiCo Inc. (NASDAQ: PEP), blue-chip consumer staple and Dividend King, has been trending higher and will soon break out to new highs. The analyst-driven trend is due to the company’s diversification strategy and dominance of the snack food aisle. The analysts have issued a steady string of... Read the Full Story |
|
Markets | | | China's economic growth accelerated in the latest quarter as consumer flocked back to shops and restaurants following the abrupt end of anti-virus controls.The 4.5% growth in gross domestic product from January to March compared to the same period in 2022 was the fastest in the past year, and outpac... Read the Full Story |
|
Markets | | | Prices for travel remain stubbornly high. The cost of airfare in February was 27% higher than the same month a year earlier, according to U.S. Bureau of Labor Statistics data . And rental car prices — having shot up during the pandemic — remain high today, as they’re 37% pricier in February than the... Read the Full Story |
|
Tuesday's Early Bird Stock Of The Day Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California. | | View Today's Stock Pick |
|
